JP3243668U6 - Functional food for symptom relief and treatment of dementia in mammals - Google Patents

Abstract

The present invention provides a functional food (oral capsule) for alleviating and treating the symptoms of dementia in mammals (excluding humans).
[Solution] We believe that the reason why treatments are not effective for dementia in dogs and cats is that the effective drug is not sufficiently distributed in the brain, so we decided to combine it with an ingredient that significantly enhances blood flow. This is an oral capsule aimed at improving the effects of blood vessels, and contains highly purified ginkgo biloba, which has unprecedented powerful blood flow effects, and contains enzymes that unclog blood vessels, nerve sheath protection, anti-inflammatory effects, and anti-oxidant effects. By combining it with leaf extract, you can obtain revolutionary symptom relief and therapeutic effects.
[Selection diagram] Figure 3

Description

The present invention relates to a functional food for alleviating and treating the symptoms of dementia in mammals including dogs and cats (excluding humans).

Currently, 25% of pet dogs in Japan are over 10 years old, and it is said that dementia begins to develop after the age of 10, and about 60% of dogs over the age of 16 suffer from dementia.

Non-Patent Document 1 discloses a functional food containing 1.5 mg of plasmalogen, 120 mg of Rumburg sulbels, 103 mg of ferulic acid, and 140 mg of ginkgo biloba extract, and further contains nutrients such as vitamin B group in a well-balanced manner. Plasmalogen is included as an intellectual nutritional ingredient, and is included as an ingredient that takes care of the ``ability to think'' and ``the ability to concentrate,'' and is useful for improving memory and ability to act. It is an ingredient created for people who are concerned about blood flow, and the supplement ingredients are included to circulate the whole body.In addition to improving liver function and high blood pressure, ferulic acid is also used to improve mild Alzheimer's disease. Ginkgo biloba extract contains flavonoid glycosides and terpene lactones, and contains it to support memory, an important element in dementia. In addition to improving concentration and judgment, it also supplements memory and cognitive functions, and is useful for elementary school students preparing for junior high school entrance exams, company managers, golf players, professional gamers, and people experiencing menopausal symptoms such as forgetfulness. It is stated that it can be used in various situations.

Patent Document 1 describes ginkgo biloba extract, which is an extract containing flavonoids, terpenoids, etc., and ginkgolide, which is a type of terpenoid contained in ginkgo biloba extract, suppresses the action of platelet activating factor (PAF). In addition to the fact that ginkgo biloba is known to have the effect of suppressing platelet aggregation and lowering blood viscosity, improving blood circulation and preventing blood coagulation (Paragraph 0010), ginkgo biloba is included in health supplements. Regarding the extract, it is described that the content of ginkgolide is 27% by weight, the content of terpene lactone is 7% by weight, and that ginkgolic acid was removed (paragraph 0016).

Patent Document 2 describes that the function-improving composition can be easily taken on a daily basis for a long period of time, and that it can be expected to prevent or improve dementia through improving brain function (Paragraph 0009), and that each tablet contains ginkgo biloba. It is stated that a drug containing 40 mg of leaf extract powder improved brain function in a dementia diagnostic test conducted according to the Hasegawa Simple Intelligence Scale.

Patent Document 3 proposes a composition containing coenzyme Q10, vitamins, and minerals in addition to plasmalogen, lumbrokinase, and ferulic acid as a composition that suppresses intracerebral inflammation and is effective in improving dementia. .
Specific composition ratios include 0.3 mg of plasmalogen and 30 mg of Lumbrokinase (Rumbulus curbelus dry powder) per tablet, and it is stated that 4.3 mg of ferulic acid was added.

Patent Document 4 discloses amyloidosis related to amyloidosis caused by the formation and deposition of amyloid plaques by increasing the activity of tissue-resident macrophages, such as bone marrow-derived microglial cells, in tissues or organs of animals in need of treatment for amyloidosis. Methods of treating diseases and disorders are disclosed.

Patent Document 5 discloses that useful ingredients contained in bird breast meat, such as anserine, carnosine, amino acids, vitamin E, phospholipids, carnitine, and coenzyme Q10, are extracted from natural sources by extracting bird breast meat using alcohol. It is disclosed that extraction is performed at a ratio close to the ratio (abundance ratio in bird breast meat).

Patent Document 6 discloses that a ginkgo diterpene lactone composition (extract) reduces neurological function evaluation in cerebral ischemia-reperfused rats, reduces cerebral ischemic area, and reduces water content after brain tissue edema. It is disclosed to improve SOD activity and reduce the content of MDA (3,4-methylenedioxyamphetamine).

Patent Document 7 describes ginkgolide-A, which is an active ingredient in ginkgo biloba extract, as an anxiolytic agent with few side effects.
Patent Document 8 discloses that docosahexaenoic acid and/or eicosapentaenoic acid, as an anti-dementia drug for animals, is administered to companion animals exhibiting dementia symptoms to improve appetite, daily rhythm, nocturnal noises, circling movements, excretory status, and paresthesias. It has been described that it can improve posture, emotional expression, and mutual relationships, and has excellent effects on improving brain function, preventing dementia, and treating dementia in companion animals.

Non-Patent Document 2 describes the use of ginkgo biloba extract for the treatment of brain diseases including Alzheimer's disease and for the treatment of vascular system diseases.

Non-Patent Document 3 reports that when ginkgo biloba extract was administered to patients with moderately severe dementia for 6 months (24 weeks), improvement was observed. It is stated that the ginkgo biloba extract used, EGb 761, contains 240 mg of standard purified ingredients that are approved for use as pharmaceuticals, containing 24% ginkgolide and 6% terpene lactone. ing.

Non-patent document 4 describes that ginkgo biloba extract was administered to patients with mild to moderate dementia, and non-patent document 5 states that ginkgo biloba extract worsened liver metastasis in a mouse colon cancer xenograft model. It is stated that

Japanese Patent Application Publication No. 2006-158351 Japanese Patent Application Publication No. 2018-70464 Japanese Patent Application Publication No. 2018-149610 Special Publication No. 2010-510219 Japanese Patent Application Publication No. 2010-063406 Special Publication No. 2021-508725 Japanese Patent Application Publication No. 2004-83553 Japanese Patent Application Publication No. 11-71274

Ziaretia [Super Light Water Co., Ltd.], waybackmachinearchive, December 5, 2021, 1685407415782_0, 1685407415782_1 2021 Apr; 11(4): 543.Published online 2021 Apr 8. doi: 1685407415782_2.3390%2Fbiom11040543Neuroprotective Herbs for the Management of Alzheimer’s Disease Psychopharmacology (Berl) 2004 Apr;172(4):430-4. doi: 10.1007/s00213-003-1675-8. Epub 2003 Nov 25.The memory-enhancing effects of Ginseng and Ginkgo biloba in healthy volunteers Psychiatr Res 2012 Jun; Ginkgo biloba extract EGb 761(R) in dementia with neuropsychiatric features: a randomized, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg Extract of Ginkgo biloba worsens liver metastasis in a mouse colon cancer Xenograft model：H Wang, X Wu, 1685407415782_3, Q Li, WG Helferich2017, Springer

Rumblekinase from red earthworms has the effect of dissolving blood clots and is known to improve blood flow in cerebral blood vessels. Plasmalogen derived from chicken breast has been shown to protect nerve cells in the brain and prevent beta-amyloid formation.

As disclosed in Patent Documents 1 to 7 and Non-Patent Documents 1 to 5, rumbulkinase from red earthworms is known to have the effect of dissolving blood clots and improve blood flow including cerebral blood vessels. Leaf extracts are known to have blood flow-promoting effects and antioxidant effects at a certain concentration or higher, but nothing has been written about improving dementia in mammals including dogs and cats (excluding humans).

In addition, as described in Patent Document 8, it has been shown that dementia in dogs can be improved by administering unsaturated fatty acids such as DHA and EPA, but the actual effects are poor and even after more than 10 years have passed. , there was still no solution to dog dementia.

No significant effects were observed with the component with β-amyloid removal function, the component that removes blood clots, or the antioxidant component alone. Therefore, in order to deliver a large amount of these substances into the blood vessels in the brain, the inventors of the present invention used highly purified ginkgo biloba extract as an ingredient that increases blood flow to an unprecedented degree and also greatly increases the duration. We thought that adding these ingredients at the same time might be effective against dementia in dogs.

That is, the functional food for alleviating and treating the symptoms of dementia in mammals (excluding humans) according to the present invention is a mixture of four drugs: rumbulkinase, ginkgo biloba extract, plasmalogen, and ferulic acid.

The ginkgo biloba extract contains ginkgolide and terpene lactone, and the purification degree of ginkgolide is 24% or more (preferably 27% or more), and the purification degree of terpene lactone is 6% or more (preferably 7% or more). do.

In addition to the four drugs Rumbulkinase, ginkgo biloba extract, plasmalogen, and ferulic acid, it also contains L-α-glycerylphosphorylcholine, astaxanthin, lecithin, diosgenin, white curcumin, taxifolin, pyrroloquinoline quinone, vitamin B group, vitamin C, Co- At least one of Q10, cinnamic acid derivative artepillin C, DHA, EPA, omega III fatty acids, phosphatidylserine, beta-lactin, vinmakiner, flavonoids and pycnogenol GABA may be added.

Ginkgo biloba extract EGB761 used in Non-Patent Document 3 has standard performance. However, if you use a highly refined ginkgo biloba extract containing 27-28% ginkgolides and 7-8% terpene lactones, it will have a much better ability to promote blood flow than the standard purified product. Our research has shown that this increases.

Additionally, ginkgo biloba extract itself has antioxidant effects, and many papers have been submitted to prevent the development and metastasis of cancer. However, as in Non-Patent Document 4, by using highly purified ginkgo biloba extract, the ability to promote blood flow becomes too strong in organs with many large blood vessels such as the liver and brain, promoting cancer metastasis. Although we are aware that it can cause blood flow, it can be said that this shows that it has a powerful ability to promote blood flow that was previously unimaginable.

By simultaneously ingesting ginkgo biloba extract, rumbulkinase, plasmalogen, and ferulic acid to enhance this blood flow promotion ability, it is possible to quickly deliver the active ingredients to their destination in the brain in large quantities over a long period of time. It can be used to treat intermediate to high-grade dementia and Lewy body dementia, including Parkinson's symptoms.

No significant effects were observed with the component with β-amyloid removal function, the component that removes blood clots, or the antioxidant component alone. Therefore, in order to deliver a large amount of these substances into the blood vessels in the brain, we added a highly purified ginkgo biloba extract component, which increases blood flow to an unprecedented degree and also greatly increases the duration. It was also found to be effective in treating dementia in dogs.

Photos showing cases of dementia in dogs Photos showing cases of dementia in dogs Photo showing an example of improvement in dementia in dogs

Tests were conducted on dogs as mammals.
In the case of dogs, as dementia (veterinally called dementia) progresses, the dog begins to spin around in the room, as shown in Figure 1, and as it progresses, the turning radius becomes smaller, and eventually the dog stops standing. Put it away. Alternatively, as shown in Figure 2, it is easy to judge the effect because it is characterized by being unable to change direction and standing frozen against the wall in the corner of the room.

The results analysis by the veterinarian in charge of the clinical test is as follows:
(1) In the case of dogs, it is characterized by its ``early'' effect, which takes place within a week, and the effects are dramatic. Figure 3 shows that the dog shown in Figure 1 has learned to walk in a straight line.
(2) Because dogs are old, they also have other diseases, making it difficult to determine whether the drugs administered are effective or not, and there are cases of dogs dying before the effects can be confirmed. (3) Since all three cases of excellent response were in Shiba Inu dogs, it is necessary to determine the differences in effectiveness depending on the breed of dog. Also, different concentrations may be needed depending on the breed of dog.
(4) Also, although it is effective for other types of dementia, it may not be effective for patients with ``disorders in vestibular function.''

Of the 11 cases shown below (table), 6 cases showed good response (including 3 cases with excellent response) and 3 cases did not respond well. 2 deaths. Among them, 3 cases had an excellent response. It can be seen that when an effect is produced, it appears within a short period of time.
That is, by orally ingesting the four drugs ``Rumblekinase,''``Plasmalogen,'' ``Ferrulic Acid,'' and ``Highly Purified Ginkgo Biloba Extract'' at the same time, brain function can be expected to improve within 30 to 60 minutes.

Improvement and alleviation of dementia can be expected by allowing mammals other than dogs and cats (excluding humans) to ingest the functional food according to the present invention.

Claims (4)

A functional food for alleviating and treating the symptoms of dementia in mammals including dogs and cats (excluding humans), which is a mixture of 4 drugs: Rumblekinase, ginkgo biloba extract, plasmalogen, and ferulic acid. . In the functional food for alleviating and treating the symptoms of dementia in mammals according to claim 1, the ginkgo biloba extract contains ginkgolide and terpene lactone, the degree of purification of ginkgolide is 24% or more, and the degree of purification of terpene lactone is 24% or more. A functional food for alleviating and treating the symptoms of dementia in mammals, characterized in that the content of the food is 6% or more. In the functional food for alleviating and treating the symptoms of dementia in mammals according to claim 1, the ginkgo biloba extract contains ginkgolide and terpene lactone, the degree of purification of ginkgolide is 27% or more, and the degree of purification of terpene lactone is 27% or more. A functional food for alleviating and treating the symptoms of dementia in mammals, characterized by having a concentration of 7% or more. In the functional food for alleviating and treating the symptoms of dementia in mammals according to claim 1, the functional food contains one of the following in addition to the four drugs Rumbulkinase, ginkgo biloba extract, plasmalogen, and ferulic acid. A functional food for alleviating and treating symptoms of brain fog, characterized by containing at least one of the following.
L-α-glycerylphosphorylcholine, astaxanthin, lecithin, diosgenin, white curcumin, taxifolin, pyrroloquinoline quinone, B vitamins, vitamin C, Co-Q10, cinnamic acid derivative artepillin C, DHA, EPA, omega III fatty acids, phosphatidylserine, GABA, beta-lactrin, bimkainer, flavonoids and pycnogenol.

Images